HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NAD

This article was originally published in The Rose Sheet

Executive Summary

The National Advertising Division of the Council of Better Business Bureaus has referred Freeman Beauty Labs to the Federal Trade Commission after the company failed to respond to the watchdog group's inquiry regarding claims for its Renewance Anti-Aging Chemical Peel, NAD reports Aug. 31. The group had requested substantiation for claims the product "offers a Pomegranate AntiOx Peptide Complex [that] restores skin's water, plumping fine lines and wrinkles," "protects against water loss and dehydration," and "delivers 92% wrinkle reduction, 88% tighter, toned skin, 92% smoother younger looking skin and 88% more radiant skin"...

You may also be interested in...



Anti-Aging Formula’s Ad Claims Unsupported By Studies – NAD

Freeman Beauty Labs will discontinue unsupported advertising claims for Renewance Anti-Aging Chemical Peel following a review by the National Advertising Division of the Council of Better Business Bureaus, which was featured in a recent Case Reports

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Partisan Politics Returns To US FDA Congressional Oversight

The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel